Asthma: NHLBI workshop on the primary prevention of chronic lung diseases

Daniel J. Jackson, Tina V. Hartert, Fernando Martinez, Scott T. Weiss, John V. Fahy

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Asthma is a common disease with enormous public health costs, and its primary prevention is an ambitious and important goal. Understanding of how host and environmental factors interact to cause asthma is incomplete, but persistent questions about mechanisms should not stop clinical research efforts aimed at reducing the prevalence of childhood asthma. Achieving the goal of primary prevention of asthma will involve integrated and parallel sets of research activities in which mechanism-oriented studies of asthma inception proceed alongside clinical intervention studies to test biologically plausible prevention ideas. For example, continued research is needed, particularly in young children, to uncover biomarkers that identify asthma risk and provide potential targets of intervention, and to improve understanding of the role of microbial factors in asthma risk and disease initiation. In terms of clinical trials that could be initiated now or in the near future, we recommend three interventions for testing: (1) preventing asthma through prophylaxis against respiratory syncytial virus and human rhinovirus infections of the airway; (2) immune modulation, using prebiotics, probiotics, and bacterial lysates; and (3) prevention of allergen sensitization and allergic inflammation, using anti-IgE. These interventions should be tested while other, more universal prevention measures that may promote lung health are also investigated. These potential universal lung health measures include prevention of preterm delivery; reduced exposure of the fetus and young infant to environmental pollutants, including tobacco smoke; prevention of maternal and child obesity; and management of psychosocial stress.

Original languageEnglish (US)
JournalAnnals of the American Thoracic Society
Volume11
Issue numberSUPPL. 3
DOIs
StatePublished - 2014

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Primary Prevention
Lung Diseases
Chronic Disease
Asthma
Education
Research
Human respiratory syncytial virus
Rhinovirus
Prebiotics
Environmental Pollutants
Lung
Pediatric Obesity
Health
Probiotics
Smoke
Health Care Costs
Allergens
Tobacco
Fetus

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Asthma : NHLBI workshop on the primary prevention of chronic lung diseases. / Jackson, Daniel J.; Hartert, Tina V.; Martinez, Fernando; Weiss, Scott T.; Fahy, John V.

In: Annals of the American Thoracic Society, Vol. 11, No. SUPPL. 3, 2014.

Research output: Contribution to journalArticle

Jackson, Daniel J. ; Hartert, Tina V. ; Martinez, Fernando ; Weiss, Scott T. ; Fahy, John V. / Asthma : NHLBI workshop on the primary prevention of chronic lung diseases. In: Annals of the American Thoracic Society. 2014 ; Vol. 11, No. SUPPL. 3.
@article{853053a73d8e4d2ebaadc67b049d3540,
title = "Asthma: NHLBI workshop on the primary prevention of chronic lung diseases",
abstract = "Asthma is a common disease with enormous public health costs, and its primary prevention is an ambitious and important goal. Understanding of how host and environmental factors interact to cause asthma is incomplete, but persistent questions about mechanisms should not stop clinical research efforts aimed at reducing the prevalence of childhood asthma. Achieving the goal of primary prevention of asthma will involve integrated and parallel sets of research activities in which mechanism-oriented studies of asthma inception proceed alongside clinical intervention studies to test biologically plausible prevention ideas. For example, continued research is needed, particularly in young children, to uncover biomarkers that identify asthma risk and provide potential targets of intervention, and to improve understanding of the role of microbial factors in asthma risk and disease initiation. In terms of clinical trials that could be initiated now or in the near future, we recommend three interventions for testing: (1) preventing asthma through prophylaxis against respiratory syncytial virus and human rhinovirus infections of the airway; (2) immune modulation, using prebiotics, probiotics, and bacterial lysates; and (3) prevention of allergen sensitization and allergic inflammation, using anti-IgE. These interventions should be tested while other, more universal prevention measures that may promote lung health are also investigated. These potential universal lung health measures include prevention of preterm delivery; reduced exposure of the fetus and young infant to environmental pollutants, including tobacco smoke; prevention of maternal and child obesity; and management of psychosocial stress.",
author = "Jackson, {Daniel J.} and Hartert, {Tina V.} and Fernando Martinez and Weiss, {Scott T.} and Fahy, {John V.}",
year = "2014",
doi = "10.1513/AnnalsATS.201312-448LD",
language = "English (US)",
volume = "11",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Asthma

T2 - NHLBI workshop on the primary prevention of chronic lung diseases

AU - Jackson, Daniel J.

AU - Hartert, Tina V.

AU - Martinez, Fernando

AU - Weiss, Scott T.

AU - Fahy, John V.

PY - 2014

Y1 - 2014

N2 - Asthma is a common disease with enormous public health costs, and its primary prevention is an ambitious and important goal. Understanding of how host and environmental factors interact to cause asthma is incomplete, but persistent questions about mechanisms should not stop clinical research efforts aimed at reducing the prevalence of childhood asthma. Achieving the goal of primary prevention of asthma will involve integrated and parallel sets of research activities in which mechanism-oriented studies of asthma inception proceed alongside clinical intervention studies to test biologically plausible prevention ideas. For example, continued research is needed, particularly in young children, to uncover biomarkers that identify asthma risk and provide potential targets of intervention, and to improve understanding of the role of microbial factors in asthma risk and disease initiation. In terms of clinical trials that could be initiated now or in the near future, we recommend three interventions for testing: (1) preventing asthma through prophylaxis against respiratory syncytial virus and human rhinovirus infections of the airway; (2) immune modulation, using prebiotics, probiotics, and bacterial lysates; and (3) prevention of allergen sensitization and allergic inflammation, using anti-IgE. These interventions should be tested while other, more universal prevention measures that may promote lung health are also investigated. These potential universal lung health measures include prevention of preterm delivery; reduced exposure of the fetus and young infant to environmental pollutants, including tobacco smoke; prevention of maternal and child obesity; and management of psychosocial stress.

AB - Asthma is a common disease with enormous public health costs, and its primary prevention is an ambitious and important goal. Understanding of how host and environmental factors interact to cause asthma is incomplete, but persistent questions about mechanisms should not stop clinical research efforts aimed at reducing the prevalence of childhood asthma. Achieving the goal of primary prevention of asthma will involve integrated and parallel sets of research activities in which mechanism-oriented studies of asthma inception proceed alongside clinical intervention studies to test biologically plausible prevention ideas. For example, continued research is needed, particularly in young children, to uncover biomarkers that identify asthma risk and provide potential targets of intervention, and to improve understanding of the role of microbial factors in asthma risk and disease initiation. In terms of clinical trials that could be initiated now or in the near future, we recommend three interventions for testing: (1) preventing asthma through prophylaxis against respiratory syncytial virus and human rhinovirus infections of the airway; (2) immune modulation, using prebiotics, probiotics, and bacterial lysates; and (3) prevention of allergen sensitization and allergic inflammation, using anti-IgE. These interventions should be tested while other, more universal prevention measures that may promote lung health are also investigated. These potential universal lung health measures include prevention of preterm delivery; reduced exposure of the fetus and young infant to environmental pollutants, including tobacco smoke; prevention of maternal and child obesity; and management of psychosocial stress.

UR - http://www.scopus.com/inward/record.url?scp=84899066468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899066468&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201312-448LD

DO - 10.1513/AnnalsATS.201312-448LD

M3 - Article

C2 - 24754822

AN - SCOPUS:84899066468

VL - 11

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - SUPPL. 3

ER -